News / Taiwan / economic_daily
Biotech Firm Enliven Therapeutics Files for Taiwan Innovation Board Listing
Health Technology · Biotechnology · economic_daily · 2026-09-22
7871
Enliven Therapeutics has officially filed for an IPO on the Taiwan Innovation Board, marking the sixth company to seek a listing on the exchange this year.
What Happened
Listing Application: The Taiwan Stock Exchange confirmed that Enliven Therapeutics has officially filed for an initial public offering on the Taiwan Innovation Board (TIB). This filing makes the company the sixth enterprise to seek a listing on the board this year, highlighting continued momentum in the biotech sector.
Business Overview: Established in 2017 and led by Chairman Chen Hong-kai, Enliven Therapeutics operates across Taipei, Hong Kong, and Shanghai. The company specializes in developing innovative immunotherapies targeting cancer, neurodegenerative diseases, and other critical immune-related conditions.
Financials and Ownership: According to the prospectus, the company has a paid-in capital of NT$1.343 billion and reported a pre-tax loss of NT$1.092 billion for the previous year. Key shareholders include the Taiwania Capital Buffalo Fund, which holds a 9.60% stake, while Chairman Chen holds 5.88% of the company.
IPO Strategy: Yuanta Securities has been appointed as the lead underwriter for the listing, with an over-allotment agreement already in place. The TIB is designed to support high-growth companies with core technologies, and this move underscores the ongoing integration between Taiwan's biomedical innovation and capital markets.